Ensidipine: a new targeted drug for the treatment of AML

Ensidipine, also known asEnasidenib, is an innovative leukemia treatment drug. It is specifically designed to treat relapsed or refractory acute myeloid leukemia (AML) that carries mutations in isocitrate dehydrogenase2 (IDH2). This drug is classified as an IDH2 inhibitor and works by interfering with abnormal cell metabolism and accelerating the death of leukemia cells.

As an oral drug, ensidipine adjusts the metabolic pathways of cells by precisely inhibiting the abnormal enzyme activity in IDH2 mutated AML patients. Since mutations in IDH2 lead to excessive accumulation of 2-hydroxyglutarate (2-HG), this can interfere with the normal function of cells and the blood production process. Ensidipine can reduce the activity of IDH2 enzyme, thereby reducing the accumulation of 2-HG, restoring the normal metabolic pathways of cells, curbing the spread of leukemia cells and accelerating their death.

Ensidipine is particularly indicated for the treatment of adult patients with relapsed or refractory AML harboring IDH2 mutations. This specific IDH2 mutation is a common genetic variant in AML that affects patient outcomes and outcomes. Ensidipine provides a new treatment method for patients with this special subtype of AML.

Clinical trial data have confirmed that ensidipine has a significant effect in reducing leukemia cells and can significantly extend the patient's survival without disease progression. For some patients, the use of ensidipine can even help them achieve complete remission (CR), thereby improving survival rates and optimizing quality of life.

Ensidipine is usually taken by mouth once daily. The specific dosage and method of taking will be adjusted according to the patient's actual situation, condition and body's response to the drug to ensure the best therapeutic effect.

In summary, ensidipine, as a new type of AML targeted therapy, brings an effective treatment option to those AML patients who carry IDH2 mutations. Its unique treatment mechanism and remarkable effects in clinical trials have brought new treatment hope to AML patients, and also opened up a new path for the research and development of leukemia treatment.